SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
J Goncalves, G Myung, MJ Park… - Therapeutic …, 2019 - journals.sagepub.com
Background: The primary objective of this study was to analyze the cross-reactivity of
antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in …
antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in …